Kyowa Kirin clocks up another FDA nod

For the second time in four months, Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) is celebrating receiving US Food and Drug Administration (FDA) approval for a rare disease drug.

The regulator has approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

"It is another important achievement in leaping forward to become a global specialty pharmaceutical company"